Feature Channels: Autoimmune Diseases

• share
• favorite_border

Here are some of the latest articles that have been added to the Clinical Trials channel on Newswise.

• share
• favorite_border

People who consume sugar and other carbohydrates in excess over a long period of time have an increased risk of developing an autoimmune disease.

• share
• favorite_border

Antiphospholipid syndrome (APS) is rare in children and known to cause inflammation and recurring, potentially fatal, blood clots. Researchers found that two-thirds of children with the autoimmune disease experienced additional symptoms not formally associated with APS, including low platelet counts, hemolytic anemia and livedo reticularis, a rash indicating abnormal blood flow to the skin. Investigators say the findings underscore the importance of creating pediatric-specific criteria for the diagnosis of APS.

• share
• favorite_border

Scientists at La Jolla Institute for Immunology (LJI) have found that people with Parkinson's disease have a clear "genetic signature" of the disease in their memory T cells. The scientists hope that targeting these genes may open the door to new Parkinson's treatments and diagnostics.

• share
• favorite_border

Don't miss these articles in our Staff Picks channel

• share
• favorite_border

Researchers found a unique immune cell plays a key role in the chronic inflammation and scarring in the lungs and skin of people with scleroderma, or systemic sclerosis. After injecting mice with biodegradable PLG nanoparticles, which are used in medical sutures, researchers found that the nanoparticles specifically targeted these inflammatory cells and prevented skin and lung fibrosis. Researchers say it's a promising step towards targeted treatment for patients with early scleroderma.

• share
• favorite_border

University of Utah Health researchers are leading a five-year, $22-million nationwide clinical trial for NMDA receptor encephalitis––a type of autoimmune encephalitis that prompts the immune system to mistakenly attack the brain, causing confusion, memory loss, seizures, and symptoms similar to bipolar disorder and other psychiatric conditions.

• share
• favorite_border

The ACR and the AAHKS released a summary of their updated guideline for the Perioperative Management of Antirheumatic Medication in Patients with Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty.

• share
• favorite_border

Studying mice, researchers at Washington University School of Medicine in St. Louis have discovered that roseolovirus can trigger autoimmunity in a previously unknown way: by disrupting the process by which immune cells learn to avoid targeting their own body's cells and tissues.

• share
• favorite_border

Researchers at La Jolla Institute for Immunology (LJI) have discovered new genes in CD4+ "helper" T cell subset that are linked to risk of autoimmune diseases. As they work to shed light on the exact functions of these CD4+ T cell subsets, the researchers have uncovered major differences between donors based on genetics and how the cells may function in men and women.

• share
• favorite_border

The ACR is launching new initiatives to reduce racial disparities in lupus clinical trials: Training to Increase Minority Enrollment in Lupus Clinical Trials with CommunitY Engagement (TIMELY) and new Continuing Medical Education (CME) for dermatologists and nephrologists.

• share
• favorite_border

A new study suggests that a single bout of exercise does not change the immune response to a coronavirus booster shot in people with rheumatic autoimmune diseases. The article is published ahead of print in the Journal of Applied Physiology.

• share
• favorite_border

Quardricos Driskell joins executive team to lead efforts to champion patient-first policies

• share
• favorite_border

A new UC Davis Health study found that taking bile acids or treatments that regulate their production may help control inflammation caused by psoriasis, a chronic skin condition.

• share
• favorite_border

The latest research news from the Health Disparities Channel.

• share
• favorite_border

La Jolla Institute for Immunology (LJI) and Kyowa Kirin, Inc. (KKNA), a wholly-owned subsidiary of Kyowa Kirin Co., Ltd (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company, today announced the signing of a new collaboration agreement. The agreement marks another milestone in one of the most enduring industry-academic collaborations in the world.

• share
• favorite_border

A new, targeted therapy, developed by researchers from the Azrieli Faculty of Medicine of Bar-Ilan University, the Albert Einstein College of Medicine, the University of Houston, and the pharmaceutical company Equillium, together with several other academic collaborators, inhibits specific immune cells associated with lupus nephritis, and was effective in improving kidney inflammation in animal models of lupus and lupus nephritis. The new approach could serve as an alternative to current treatments targeting multiple immune cells, and provide a more effective and potentially personalized remedy for lupus nephritis. The development was recently reported in the Journal of Clinical Investigation.

• share
• favorite_border

A first-in-kind immune-modulating drug that arose from decades of basic research at UT Southwestern Medical Center has received approval from the U.S. Food and Drug Administration as a new treatment for adults with a form of myasthenia gravis. This rare and chronic autoimmune disease is characterized by debilitating and potentially life-threatening muscle weakness.